Promore Pharma has conducted Investigator Meeting for HEAL LL-37 in Poland
STOCKHOLM, 6 September 2018 -- Promore Pharma AB, a Swedish biopharmaceutical developer of therapeutic peptides, today announced that the company has hosted an Investigator Meeting for the HEAL study on 4-5 September 2018 in Warsaw, Poland. The clinical trial HEAL is the Phase IIb study with the company’s product candidate LL-37 for treatment of venous leg ulcers.The meeting gathered physicians, nurses and study coordinators from all clinics in Poland that will participate in the HEAL study and representatives for Promore Pharma, Clinical Research Organisation PCG Clinical Services and